Medicare Part B suppliers may deliver the initial immunosuppressive drugs prescribed to a beneficiary after a transplant procedure to an address other than their home to ensure timely access to the medications at discharge, the Centers for Medicare & Medicaid Services announced last week in updated guidance. “In certain cases, a beneficiary who has received a transplant does not return home immediately after discharge,” the guidance states. “In order to ensure timely beneficiary access to prescribed immunosuppressive medications at the time of discharge, suppliers may deliver the initial prescriptions of a beneficiary’s immunosuppressive drugs to an alternate address, such as the transplant facility or alternative location where the beneficiary is temporarily staying, for example, temporary housing, instead of delivering the drugs to the patient’s home address.” AHA advocated for the policy change.

Related News Articles

Headline
The Department of Health and Human Services as of July 1 has reduced by nearly 20% its backlog of Medicare appeals at the Administrative Law Judge level,…
Headline
The Centers for Medicare & Medicaid Services this week released final Medicare Advantage data on services provided to beneficiaries in calendar year 2015.
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.
Headline
The Centers for Medicare…
Headline
The Centers for Medicare…
Headline
The Centers for Medicare…